2025-05-01 2026-04-30 2026-04-30 false 15671601 Doctor Sara Dowsett Limited 86900Other human health activities iso4217:GBP xbrli:pure 156716012025-05-01 156716012026-04-30 156716012025-05-01 2026-04-30 15671601bus:SmallEntities2025-05-01 2026-04-30 15671601bus:AuditExempt-NoAccountantsReport2025-05-01 2026-04-30 15671601bus:FullAccounts2025-05-01 2026-04-30 15671601core:WithinOneYear2026-04-30 15671601core:AfterOneYear2026-04-30 15671601core:WithinOneYear2025-05-01 2026-04-30 15671601core:AfterOneYear2025-05-01 2026-04-30 15671601core:CurrentFinancialInstruments2026-04-30 15671601core:Non-currentFinancialInstruments2026-04-30 15671601core:CurrentFinancialInstruments2025-05-01 2026-04-30 15671601core:Non-currentFinancialInstruments2025-05-01 2026-04-30 15671601core:LandBuildings2025-05-01 2026-04-30 15671601core:FurnitureFittings2025-05-01 2026-04-30 15671601core:OfficeEquipment2025-05-01 2026-04-30 15671601core:Vehicles2025-05-01 2026-04-30 15671601core:PlantMachinery2025-05-01 2026-04-30 15671601core:OtherPropertyPlantEquipment2025-05-01 2026-04-30 15671601core:LandBuildings2026-04-30 15671601core:PlantMachinery2026-04-30 15671601core:Vehicles2026-04-30 15671601core:FurnitureFittings2026-04-30 15671601core:OfficeEquipment2026-04-30 15671601core:OtherPropertyPlantEquipment2026-04-30 15671601core:Right-of-useAssets2025-05-01 2026-04-30 15671601core:Right-of-useAssets2026-04-30 15671601core:Goodwill2025-05-01 2026-04-30 15671601core:PatentsTrademarksLicencesConcessionsSimilar2025-05-01 2026-04-30 15671601core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-05-01 2026-04-30 15671601core:OtherResidualIntangibleAssets2025-05-01 2026-04-30 15671601core:Goodwill2026-04-30 15671601core:DevelopmentCostsCapitalisedDevelopmentExpenditure2026-04-30 15671601core:PatentsTrademarksLicencesConcessionsSimilar2026-04-30 15671601core:OtherResidualIntangibleAssets2026-04-30 15671601dpl:CostSales2025-05-01 2026-04-30 15671601dpl:AdministrativeExpenses2025-05-01 2026-04-30 15671601dpl:DistributionCosts2025-05-01 2026-04-3015671601core:ShareCapital2026-04-30 15671601core:SharePremium2026-04-30 15671601core:RevaluationReserve2026-04-30 15671601core:OtherReservesSubtotal2026-04-30 15671601core:ShareCapitalPreferenceShares2026-04-30 15671601core:CapitalRedemptionReserve2026-04-30 15671601core:OtherCapitalReserve2026-04-30 15671601core:RetainedEarningsAccumulatedLosses2026-04-3015671601core:ShareCapital2025-05-01 2026-04-30 15671601core:SharePremium2025-05-01 2026-04-30 15671601core:RevaluationReserve2025-05-01 2026-04-30 15671601core:OtherReservesSubtotal2025-05-01 2026-04-30 15671601core:RetainedEarningsAccumulatedLosses2025-05-01 2026-04-301567160112025-05-01 2026-04-30 1567160122025-05-01 2026-04-3015671601core:ShareCapital12025-05-01 2026-04-30 15671601core:ShareCapital22025-05-01 2026-04-3015671601core:SharePremium12025-05-01 2026-04-30 15671601core:SharePremium22025-05-01 2026-04-3015671601core:RevaluationReserve12025-05-01 2026-04-30 15671601core:RevaluationReserve22025-05-01 2026-04-3015671601core:RetainedEarningsAccumulatedLosses12025-05-01 2026-04-30 15671601core:RetainedEarningsAccumulatedLosses22025-05-01 2026-04-301567160112025-05-01 2026-04-3015671601core:Non-currentFinancialInstrumentscore:CostValuation2025-05-01 15671601core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-04-30 15671601core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-04-30 15671601core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-04-30 15671601core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2026-04-30 15671601core:Non-currentFinancialInstrumentscore:CostValuation2026-04-3015671601core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-05-01 15671601core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-04-30 15671601core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-04-30 15671601core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-04-30 15671601core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2026-04-30 15671601core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-04-30 15671601core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2026-04-3015671601core:Non-currentFinancialInstruments2026-04-30 15671601core:Non-currentFinancialInstruments2025-04-30156716012024-04-23 156716012025-04-30 156716012024-04-23 2025-04-30 15671601core:WithinOneYear2025-04-30 15671601core:AfterOneYear2025-04-30 15671601core:CurrentFinancialInstruments2025-04-30 15671601core:Non-currentFinancialInstruments2025-04-30 15671601core:LandBuildings2025-04-30 15671601core:PlantMachinery2025-04-30 15671601core:Vehicles2025-04-30 15671601core:FurnitureFittings2025-04-30 15671601core:OfficeEquipment2025-04-30 15671601core:OtherPropertyPlantEquipment2025-04-30 15671601core:Right-of-useAssets2025-04-30 15671601core:Goodwill2025-04-30 15671601core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-04-30 15671601core:PatentsTrademarksLicencesConcessionsSimilar2025-04-30 15671601core:OtherResidualIntangibleAssets2025-04-30 15671601dpl:AdministrativeExpenses2024-04-23 2025-04-3015671601core:ShareCapital2025-04-30 15671601core:SharePremium2025-04-30 15671601core:RevaluationReserve2025-04-30 15671601core:OtherReservesSubtotal2025-04-30 15671601core:ShareCapitalPreferenceShares2025-04-30 15671601core:CapitalRedemptionReserve2025-04-30 15671601core:OtherCapitalReserve2025-04-30 15671601core:RetainedEarningsAccumulatedLosses2025-04-3015671601core:RetainedEarningsAccumulatedLosses2024-04-23 15671601core:ShareCapital2024-04-23 15671601core:SharePremium2024-04-23 15671601core:RevaluationReserve2024-04-23 15671601core:ShareCapital2024-04-23 2025-04-30 15671601core:SharePremium2024-04-23 2025-04-30 15671601core:RevaluationReserve2024-04-23 2025-04-30 15671601core:OtherReservesSubtotal2024-04-23 2025-04-30 15671601core:RetainedEarningsAccumulatedLosses2024-04-23 2025-04-301567160112024-04-23 2025-04-30 1567160122024-04-23 2025-04-3015671601core:ShareCapital12024-04-23 2025-04-30 15671601core:ShareCapital22024-04-23 2025-04-3015671601core:SharePremium12024-04-23 2025-04-30 15671601core:SharePremium22024-04-23 2025-04-3015671601core:RevaluationReserve12024-04-23 2025-04-30 15671601core:RevaluationReserve22024-04-23 2025-04-3015671601core:RetainedEarningsAccumulatedLosses12024-04-23 2025-04-30 15671601core:RetainedEarningsAccumulatedLosses22024-04-23 2025-04-3015671601bus:Director12025-05-01 2026-04-3015671601bus:Director22025-05-01 2026-04-3015671601bus:PrivateLimitedCompanyLtd2025-05-01 2026-04-30
Doctor Sara Dowsett Limited
Unaudited Financial Statements
for the year ended 30 April 2026
Company registration number 15671601
(England and Wales)

Company Information

For the year ended 30 April 2026
Directors Dowsett, Adam
Dowsett, Sara

Registered office Bourne House
23 Hinton Road
Bournemouth
BH1 2EF

Registered number 15671601

Accountant 2020 ACCOUNTANCY
Bourne Space
Bourne House
23 Hinton Road
Bournemouth
Bournemouth
BH1 2EF

Statement of Financial Position

As at 30 April 2026
Notes
2026
2025
£
£
£
£
Current assets
Debtors
4
7,724
11,229
Cash at bank and in hand
9,695
673
17,419
11,902
Creditors
Amounts falling due within one year
5
(17,368)
(11,894)
(17,368)
(11,894)
Net current assets (liabilities)
51
8
Total assets less current liabilities
51
8
Net assets (liabilities)
51
8
Capital and reserves
Called up share capital
1
1
Profit and loss account
50
7
Total equity
51
8

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 8 July 2026 and are signed on its behalf by:

Dowsett, Adam
Dowsett, Adam
Director
Dowsett, Sara
Dowsett, Sara
Director

Company registration number 15671601

Notes to the Financial Statements

For the year ended 30 April 2026

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

3. Employees

The average number of employees during the year was 0 (2025: 0).

4. Debtors

2026
2025
£
£
Directors loan accounts
7,724
11,229
Total due within one year
7,724
11,229
Total due after one year
-
-
Total
7,724
11,229

5. Creditors due within one year

2026
2025
£
£
Taxation and social security
17,368
11,894
Total
17,368
11,894

6. Directors advances, credits and guarantees

Director
Amounts advanced
Carried forward
£
£
Dowsett, Sara
3,862
3,862
Dowsett, Adam
3,862
3,862
Total
7,724
7,724

The above loan is unsecured, interest free and repayable on demand.